Aclaris Therapeutics (ACRS) Capital Expenditures (QoQ) (2015 - 2026)

Aclaris Therapeutics (ACRS) Capital Expenditures (QoQ) (2015 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn
7 Royalty Pharma 33.72 Bn 35.84 Bn -
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn
10 Aclaris Therapeutics 808.18 Mn 716.63 Mn 1.41 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -81.67%
Mar 31, 2026 -39.39%
Dec 31, 2025 290.38%
Sep 30, 2025 -347.62%
Jun 30, 2025 -51.16%
Jun 30, 2024 -110.37%
Mar 31, 2024 -85.53%
Dec 31, 2023 5,283.33%
Sep 30, 2023 -105.10%
Jun 30, 2023 760.98%
Mar 31, 2023 108.61%
Dec 31, 2022 -417.33%
Sep 30, 2022 -37.24%
Jun 30, 2022 115.32%
Mar 31, 2022 -44.50%
Dec 31, 2021 257.14%
Dec 31, 2020 -97.37%
Sep 30, 2020 1,688.24%
Jun 30, 2020 -86.29%
Mar 31, 2020 -91.18%